HBG1 and Schnyder corneal dystrophy: The phase 1/2 clinical trial NCT05456880 led by Beam Therapeutics Inc. aimed to generate an A to G base swap in the HBG1/2 promoters via base editing to mimic HPFH in severe SCD patients and represented the first clinical trial of a base editor in the United States.